Bionostics in possible buyout talk:
This article was originally published in Clinica
Executive Summary
Bionostics, the medical diagnostics business formerly known as the Ferrari Group, last week (June 8) confirmed that it is in discussions with an unnamed party, which could lead to a possible takeover bid. The Birmingham, UK-based company saw its share price on the London AIM stock exchange rise by around 22% in the week after the announcement, rising from 23.5p to 28.25p ($46.40 to $55.78), and peaking at 31p. Bionostics provides a broad range of products and services in the liquid control and cryosystem sectors of the diagnostics industry.